Asia Pacific Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)

Description

List of Tables

The Asia Pacific vaccine adjuvants market was valued at US$ 518.07 million in 2022 and is expected to reach US$ 1,546.43 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030 .

Advancements in Biotechnology and Immunology Boost Asia Pacific Vaccine Adjuvants Market

The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.

Asia Pacific Vaccine Adjuvants Market Overview

The Asia Pacific vaccine adjuvant market has been segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Strategic initiatives, such as collaborations between Chinese companies to produce adjuvant vaccines, drive the market. For instance, in April 2020, Dynavax Technologies Corporation announced a collaboration with Chinese biopharmaceutical company Sinovac to develop CpG 1018 adjuvant. CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the US Food and Drug Administration (FDA) to increase vaccine immune response. Therefore, strategic developments such as collaboration and partnerships by the Chinese manufacturers for procuring adjuvanted vaccines is a standalone factor responsible for positive market growth.

Asia Pacific Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Vaccine Adjuvants Market Segmentation

The Asia Pacific vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Asia Pacific vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Asia Pacific vaccine adjuvants market share in 2022.

By type, the Asia Pacific vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Asia Pacific vaccine adjuvants market in 2022.

By country, the Asia Pacific vaccine adjuvants market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific vaccine adjuvants market.

Product Code: BMIRE00031082

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics

4.1 Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
- 4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
- 4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunity
- 4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
- 4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Asia Pacific Market Analysis

5.1 Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
5.2 Asia Pacific Vaccine Adjuvants Market Forecast and Analysis

6. Asia Pacific Vaccine Adjuvants Market Analysis - by Adjuvant Class

6.1 Overview
6.2 Mineral Salt Adjuvant
- 6.2.1 Overview
- 6.2.2 Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
- 6.3.1 Overview
- 6.3.2 Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
- 6.4.1 Overview
- 6.4.2 Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Vaccine Adjuvants Market Analysis - by Type

7.1 Human Vaccine Adjuvant
- 7.1.1 Overview
- 7.1.2 Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
- 7.2.1 Overview
- 7.2.2 Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Vaccine Adjuvants Market -Country Analysis

8.1 Asia Pacific
- 8.1.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 8.1.1.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.1 Overview
    - 8.1.1.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.1 Overview
    - 8.1.1.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.1 Overview
    - 8.1.1.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.1 Overview
    - 8.1.1.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.5.1 Overview
    - 8.1.1.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.6.1 Overview
    - 8.1.1.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Vaccine Adjuvants Market
9.3 Organic Developments
- 9.3.1 Overview
9.4 Inorganic Developments
- 9.4.1 Overview

10. Company Profiles

10.1 SPI Pharma Inc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 GSK Plc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 CSL Ltd
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Hawaii Biotech Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 InvivoGen SAS
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Croda International Plc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Novavax Inc
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Phibro Animal Health Corp
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments

11. Appendix

11.1 About The Insight Partners